^
BIOMARKER:

EGFR C797S

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR C797S
LUAD
brigatinib
Sensitive: C3 – Early Trials
Cancer Med - 1 week
EGFR C797S
NSCLC
amivantamab-vmjw
Sensitive: C2 – Inclusion Criteria
EGFR C797S
NSCLC
U3-1402
Sensitive: C3 – Early Trials
EGFR C797S
NSCLC
osimertinib
Resistant: C3 – Early Trials
EGFR C797S
Lung Cancer
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
EGFR C797S
NSCLC
olmutinib
Resistant: C3 – Early Trials
EGFR C797S
NSCLC
rociletinib
Resistant: C3 – Early Trials
EGFR C797S
NSCLC
WZ4002
Resistant: C3 – Early Trials
EGFR C797S
NSCLC
cetuximab + brigatinib
Sensitive: C3 – Early Trials
EGFR C797S
LUAD
osimertinib
Resistant: C4 – Case Studies
EGFR C797S
NSCLC
APG-1252
Sensitive: D – Preclinical
EGFR C797S
LUAD
Notch inhibitor + osimertinib
Sensitive: D – Preclinical
EGFR C797S
Lung Cancer
afatinib
Sensitive: D – Preclinical
EGFR C797S
Lung Cancer
erlotinib
Sensitive: D – Preclinical